Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.43 |
| ▸ | DUT | P33316 | 1/20 | 0.42 |
| ▸ | PDE4A | P27815 | 12/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL22723238 | 0.98 | APP (0.42) | APPDUTPDE4APTGS1PTGS2 | |
| Hydrochloric Acid SCHEMBL22723239 | 0.98 | APP (0.42) | APPDUTPDE4APTGS1PTGS2 | |
| SCHEMBL16203391 | 0.89 | APP (0.43) | APPDUTPDE4APTGS1PTGS2 | |
| SCHEMBL9989172 | 0.88 | APP (0.45) | APPPDE4APTGS1PTGS2HIF1A | |
| SCHEMBL13091309 | 0.88 | DUT (0.44) | APPDUTPDE4APTGS1PTGS2 | |
| SCHEMBL12810266 | 0.87 | PDE4D (0.45) | DUTPDE4APDE4BPDE4DPDE4C | |
| SCHEMBL21690290 | 0.85 | PTGS1 (0.43) | APPDUTPDE4APTGS1PTGS2 | |
| SCHEMBL21533928 | 0.84 | DUT (0.41) | APPDUTPDE4APTGS1PTGS2 | |
| SCHEMBL22170165 | 0.82 | DUT (0.48) | APPDUTPDE4APTGS1PTGS2 | |
| SCHEMBL15247548 | 0.82 | DUT (0.48) | APPDUTPDE4APTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508185-A1 | ANTI-TUMOR EFFECT POTENTIATOR | Taiho Pharmaceutical Co., Ltd. (JP) | 2012-10-10 | — | — | EP | disclosed |
| EP-2295414-B1 | URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2012-09-26 | — | — | EP | disclosed |
| US-20120225838-A1 | ANTI-TUMOR EFFECT POTENTIATOR | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2012-09-06 | — | — | US | disclosed |
| WO-2011065545-A1 | 5-FLUOROURACIL COMPOUND HAVING dUTPase-INHIBITING ACTIVITY OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| WO-2011065541-A1 | ANTI-TUMOR EFFECT POTENTIATOR | 大鵬薬品工業株式会社 (JP) | 2011-06-03 | — | — | WO | disclosed |
| EP-2295414-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009147843-A1 | NOVEL URACIL COMPOUND HAVING INHIBITORY ACTIVITY ON HUMAN DEOXYURIDINE TRIPHOSPHATASE OR SALT THEREOF | 大鵬薬品工業株式会社 (JP) | 2009-12-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225838-A1 | ANTI-TUMOR EFFECT POTENTIATOR | CCNT1, CCNA1, UPP1 | APP 4793/4885DUT 305/4885PDE4A 2346/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.